Vintafolide: a novel targeted agent for epithelial ovarian cancer.

Abstract

Vintafolide (EC145) is a novel folate-conjugated vinca alkaloid (desacetylvinblastine hydrazide; DAVBLH) that binds with high affinity to the folate receptor (FR), expressed in a majority of epithelial ovarian cancers. In preclinical studies, vintafolide had significant antiproliferative activity and tolerability. Phase I studies demonstrated an acceptable safety profile, with constipation being the dose-limiting toxicity. A Phase II study of vintafolide plus pegylated liposomal doxorubicin (PLD) versus PLD alone in patients with platinum-resistant ovarian cancer showed a statistically significant improvement in progression-free survival with combination therapy. (99m)Tc-etarfolatide, a diagnostic radiopharmaceutical, determines FR status, which allows determination of those patients most likely to benefit from treatment with vintafolide. A Phase III study evaluating vintafolide plus PLD versus PLD alone in patients with platinum-resistant ovarian cancer is currently underway.

• Authors: Whitney S Graybill, Robert L Coleman
• Journal: Future oncology (London, England) (Future Oncol) Vol. 10 Issue 4 Pg. 541-8 (Mar 2014) ISSN: 1744-8301 [Electronic] England
• PMID: 24754586 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents
• EC145
• Vinca Alkaloids
• Folic Acid

Topics

• Animals
• Antineoplastic Agents (chemistry, pharmacology, therapeutic use)
• Carcinoma, Ovarian Epithelial
• Clinical Trials as Topic
• Drug Evaluation, Preclinical
• Female
• Folic Acid (analogs & derivatives, chemistry, pharmacology, therapeutic use)
• Humans
• Molecular Targeted Therapy
• Neoplasms, Glandular and Epithelial (diagnosis, drug therapy)
• Ovarian Neoplasms (diagnosis, drug therapy)
• Treatment Outcome
• Vinca Alkaloids (chemistry, pharmacology, therapeutic use)